Recent

% | $
Quotes you view appear here for quick access.

Inovio Pharmaceuticals, Inc. Message Board

  • garysnoop1 garysnoop1 Sep 23, 2013 7:45 AM Flag

    A not on CELLECTRA electroportation for those who may have forgotten..

    Inovio's patented CELLECTRA electroporation delivery technology uses controlled, millisecond electrical pulses to create temporary pores in the cell membrane and allow significant cellular uptake of a synthetic DNA vaccine previously injected into muscle or skin. This technique has been shown to increase gene expression of the encoded "antigen" by as much as 1000-fold compared to vaccination without electroporation. Inovio's cutting-edge DNA and electroporation technology also avoids issues that have plagued some other vaccine platforms: for example, researchers have observed that some vector-based vaccines may be associated with the lessening of immune responses driven by vaccination. The two HIV phase I trials, HVTN 070 (without electroporation; n=120 patients); and 080 (with electroporation; n=48 patients); were multicenter, randomized, clinical trials. The studies were sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), an agency of the National Institutes of Health, and conducted by the NIAID-funded HIV Vaccine Trials Network (HVTN) at several clinical sites. The HIV Vaccine Trials Network (HVTN), headquartered at Fred Hutchinson Cancer Research Center in Seattle, WA, is an international collaboration of scientists and educators searching for an effective and safe HIV vaccine. The HVTN's mission is to facilitate the process of testing preventive vaccines against HIV/AIDS. The HVTN conducts all phases of clinical trials, from evaluating experimental vaccines for safety and the ability to stimulate immune responses, to testing vaccine efficacy. Support for the HVTN comes from the National Institute of Allergy and Infectious Diseases (NIAID) of the U.S. National Institutes of Health (NIH). The Network's HIV Vaccine Trial Units are located at leading research institutions in 27 cities on four continents. Internationally renowned HIV vaccine and prevention researchers lead the units. Inovio is revolutionizing vaccines as we know them

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
INO
10.36-0.52(-4.78%)4:00 PMEDT